An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Change in Adult Investigator Symptom Rating Scale (AISRS) Scores From Baseline
研究概览
简要总结
The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults. Medications that increase dopamine are often effective in treating ADHD in adults. Since naltrexone is a kappa opioid receptor antagonist, it increases dopamine in the brain.
We predict that naltrexone as a monotherapy will be effective for ADHD symptoms in adults with ADHD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Naltrexone
Naltrexone
干预措施: Naltrexone (Drug)
结局指标
主要结局
Change in Adult Investigator Symptom Rating Scale (AISRS) Scores From Baseline
时间窗: Baseline and Six weeks
The Adult Investigator Symptom Rating Scale (AISRS) is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (none) to 3 (severe). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms).
次要结局
- Clinical Global Impression (CGI)(Six weeks)
研究者
Thomas J. Spencer, MD
Principal Investigator
Massachusetts General Hospital